Get notified of page updates

Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel for Recurrent or Primary Advanced Endometrial Cancer (RUBY)

Metastatic endometrial cancer

Clinicaltrials.gov identifier:
NCT03981796

Phase 3

Study Contact Information:

For additional information, please contact: US GSK Clinical Trials Call Center by phone:  877-379-3718 or by email: [email protected]          

PRINTER FRIENDLY PAGE
Overview
Who Can Join
Contact
Glossary on
off

About the Study

This study for people with III or IV will look at how well the combination of the dostarlimab (Jemperli), the niraparib () and chemotherapy works compared with chemotherapy alone. NOTE: This study is no longer enrolling people. 

This Study is Open To:

NOTE: This study is no longer enrolling people. 

This Study is NOT Open To:

NOTE: This study is no longer enrolling people. 

Study Contact Information:

For additional information, please contact: US GSK Clinical Trials Call Center by phone:  877-379-3718 or by email: [email protected]          

Metastatic endometrial cancer

Clinicaltrials.gov identifier:
NCT03981796

Phase 3

Study Contact Information:

For additional information, please contact: US GSK Clinical Trials Call Center by phone:  877-379-3718 or by email: [email protected]          

PRINTER FRIENDLY PAGE